Cannabis Use and Age at Onset of Symptoms in Subjects at Clinical High Risk for Psychosis
Overview
Authors
Affiliations
Objective: Numerous studies have found a robust association between cannabis use and the onset of psychosis. Nevertheless, the relationship between cannabis use and the onset of early (or, in retrospect, prodromal) symptoms of psychosis remains unclear. The study focused on investigating the relationship between cannabis use and early and high-risk symptoms in subjects at clinical high risk for psychosis.
Method: Prospective multicenter, naturalistic field study with an 18-month follow-up period in 245 help-seeking individuals clinically at high risk. The Composite International Diagnostic Interview was used to assess their cannabis use. Age at onset of high risk or certain early symptoms was assessed retrospectively with the Interview for the Retrospective Assessment of the Onset of Schizophrenia.
Results: Younger age at onset of cannabis use or a cannabis use disorder was significantly related to younger age at onset of six symptoms (0.33 < r(s) < 0.83, 0.004 < P < 0.001). Onset of cannabis use preceded symptoms in most participants.
Conclusion: Our results provide support that cannabis use plays an important role in the development of psychosis in vulnerable individuals. Cannabis use in early adolescence should be discouraged.
Clinical Effects of Cannabis Use in First-Episode Acute Psychotic Patients.
Akdoner B, Baklaci U, Tuncel O, Aldemir E, Elbi H Noro Psikiyatr Ars. 2023; 60(4):363-369.
PMID: 38077836 PMC: 10709701. DOI: 10.29399/npa.28401.
Influence of cannabis use on incidence of psychosis in people at clinical high risk.
Chester L, Valmaggia L, Kempton M, Chesney E, Oliver D, Hedges E Psychiatry Clin Neurosci. 2023; 77(9):469-477.
PMID: 37070555 PMC: 7615575. DOI: 10.1111/pcn.13555.
Kaur N, Bastien G, Gagnon L, Graham J, Mongeau-Perusse V, Bakouni H Front Psychiatry. 2022; 13:973988.
PMID: 36299544 PMC: 9590692. DOI: 10.3389/fpsyt.2022.973988.
Lawn W, Mokrysz C, Lees R, Trinci K, Petrilli K, Skumlien M J Psychopharmacol. 2022; 36(12):1350-1361.
PMID: 35772419 PMC: 9716489. DOI: 10.1177/02698811221108956.
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.
Navarro D, Gasparyan A, Navarrete F, Torregrosa A, Rubio G, Marin-Mayor M Int J Mol Sci. 2022; 23(9).
PMID: 35563156 PMC: 9104141. DOI: 10.3390/ijms23094764.